logo
TreeHouse Foods, Inc. Reports First Quarter 2025 Results

TreeHouse Foods, Inc. Reports First Quarter 2025 Results

Yahoo06-05-2025

The net sales decrease of 3.5% was primarily due to unfavorable volume/mix related to planned margin management actions, broader macroeconomic consumption trends, and service impacts related to the voluntary recall of frozen griddle products. Additionally, the RTD business exit contributed to the decrease. This was partially offset by the acquisition of the private brand tea business, favorable pricing to recover commodity inflation, and distribution gains.
Net Sales — Net sales for the first quarter of 2025 totaled $792.0 million compared to $820.7 million for the same period last year, a decrease of $28.7 million, or 3.5%. The change in net sales from 2024 to 2025 was due to the following:
Mr. Oakland continued, "As we look ahead, we are remaining steadfast in the plan I articulated last quarter. We are controlling the controllables and ensuring that we provide best in class service for our retail customers at a time when they need us. These actions have and will enable us to grow profits and cash flow regardless of the environment and position the business for significant operating leverage when our categories return to higher growth rates."
"I am grateful to the entire TreeHouse team for its execution this quarter, which resulted in Adjusted EBITDA that exceeded the upper-end of our guidance range," said Steve Oakland, Chairman, Chief Executive Officer, and President. "We restored production capacity at our Brantford frozen griddle facility and implemented plans to drive margin and execution consistent with our focus on profitability and cash flow growth. I continue to believe private brands are well positioned to offer value to our customers and the consumer."
OAK BROOK, Ill., May 6, 2025 /PRNewswire/ -- TreeHouse Foods, Inc. (NYSE: THS) today reported financial results for the first quarter of 2025.
Reaffirmed 2025 outlook of adjusted net sales of $3.34 to $3.40 billion, adjusted EBITDA of $345 to $375 million, and free cash flow 2 of at least $130 million.
Story Continues
Gross Profit — Gross profit as a percentage of net sales was 14.5% in the first quarter of 2025, compared to 13.6% in the first quarter of 2024, an increase of 0.9 percentage points. The increase in Gross profit is primarily due to the execution of supply chain savings initiatives, favorable pricing to recover commodity inflation, and a mix benefit from Harris Tea.
Total Operating Expenses — Total operating expenses were $120.7 million in the first quarter of 2025 compared to $117.2 million in the first quarter of 2024, an increase of $3.5 million. The increase is due to increased restructuring costs primarily related to severance expense, which was partially offset by lower freight and commission costs.
Total Other Expense — Total other expense was $38.1 million in the first quarter of 2025 compared to $10.1 million in the first quarter of 2024, an increase in expense of $28.0 million. This was primarily due to a $24.0 million unfavorable change in non-cash mark-to-market impact from hedging activities, largely driven by interest rate swaps. Additionally, the Company had an increase of $3.7 million in interest expense primarily due to an increase in borrowings on our Revolving Credit Facility and a loss on extinguishment of debt of $2.6 million during the first quarter of 2025. This was partially offset by a favorable currency exchange rate impact of $3.7 million between the U.S. and Canada.
Income Taxes — Income taxes were recognized at an effective rate of 27.1% in the first quarter of 2025 compared to 23.5% recognized in the first quarter of 2024. The change in the Company's effective tax rate is primarily driven by changes in the amounts of executive compensation that is not deductible for tax purposes and the estimated amount of annual pre-tax earnings.
Net Loss and Adjusted EBITDA — Net loss for the first quarter of 2025 was $31.8 million, compared to $11.7 million for the same period of the previous year. Adjusted EBITDA1 was $57.5 million in the first quarter of 2025, compared to $46.0 million in the first quarter of 2024, an increase of $11.5 million. The increase in Adjusted EBITDA is primarily due to supply chain savings initiatives, favorable pricing to recover commodity inflation, and the accretive impact of the Harris Tea acquisition.
Net Cash Used In Operating Activities — Net cash used in operating activities was $53.5 million in the first three months of 2025 compared to $52.4 million in the first three months of 2024, an increase in cash used of $1.1 million, which was mostly attributable to timing of working capital.
OUTLOOK2
TreeHouse Foods reiterated its previously issued full year 2025 guidance:
Adjusted net sales in a range of $3.340 billion to $3.400 billion, which represents a decline of approximately 1% to growth of approximately 1% year-over-year driven by: Volume/mix, which are expected to decline approximately 1% year-over-year due to: Organic volume/mix decline approximately 1% Harris Tea volume benefit offset by previously announced decision to exit the Ready-to-drink ("RTD") business and other margin management actions, along with one-time impact of frozen griddle product recall. Pricing, which is expected to provide an approximately 1% benefit.
Adjusted EBITDA is expected in a range of $345 million to $375 million.
Net interest expense is continued to be expected in the range of $80 to $90 million.
The Company expects capital expenditures of approximately $125 million.
The Company expects free cash flow of at least $130 million.
With regard to the second quarter, TreeHouse Foods expects the following:
Second quarter adjusted net sales are expected in a range of $785 to $800 million, which represents approximately flat growth year-over-year at the mid-point. Organic volume and mix are expected to decline mid-single digits, driven primarily by continued margin management actions and the griddle product recall. Pricing is expected to provide an approximately 1% benefit.
Second quarter adjusted EBITDA is expected in a range of $61 to $71 million, which reflects the shift of $6 million of spend into Q2 from Q1.
________________________________________________
1 Adjusted EBITDA, adjusted net sales, and free cash flow are non-GAAP financial measures. See "Comparison of Non-GAAP Information to GAAP Information" for the definitions of the Non-GAAP measures, information concerning certain items affecting comparability, and reconciliations of GAAP to Non-GAAP measures.
2 The Company is not able to reconcile prospective adjusted net sales, adjusted EBITDA or free cash flow, which are Non-GAAP financial measures, to the most comparable GAAP financial measures without unreasonable effort due to the inherent uncertainty and difficulty of predicting the occurrence, financial impact, and timing of certain items impacting GAAP results. These items include, but are not limited to, mark-to-market adjustments of derivative contracts, foreign currency exchange on the re-measurement of intercompany notes, or other non-recurring events or transactions that may significantly affect reported GAAP results.
CONFERENCE CALL WEBCAST
A webcast to discuss the Company's first quarter earnings will be held at 8:30 a.m. (Eastern Time) today. The live audio webcast and a supporting slide deck will be available on the Company's website at www.treehousefoods.com/investors/investor-overview/default.aspx .
COMPARISON OF NON-GAAP INFORMATION TO GAAP INFORMATION
The Company has included in this release measures of financial performance that are not defined by GAAP ("Non-GAAP"). A Non-GAAP financial measure is a numerical measure of financial performance that excludes or includes amounts so as to be different than the most directly comparable measure calculated and presented in accordance with GAAP in the Company's Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Operations, Condensed Consolidated Statements of Comprehensive Loss, Condensed Consolidated Statements of Stockholders' Equity, and the Condensed Consolidated Statements of Cash Flows. As described further below, the Company believes these measures provide useful information to the users of the financial statements.
For each of these Non-GAAP financial measures, the Company provides a reconciliation between the most directly comparable GAAP measure and the Non-GAAP measure, an explanation of why management believes the Non-GAAP measure provides useful information to financial statement users, and any additional purposes for which management uses the Non-GAAP measure. This Non-GAAP financial information is provided as additional information for the financial statement users and is not in accordance with, or an alternative to, GAAP. These Non-GAAP measures may be different from similar measures used by other companies.
EBITDA, EBITDA Margin, Adjusted EBITDA, and Adjusted EBITDA Margin, Adjusting for Certain Items Affecting Comparability
EBITDA margin is defined as EBITDA as a percentage of net sales. Adjusted EBITDA margin is defined as adjusted EBITDA as a percentage of adjusted net sales. EBITDA represents net loss before interest expense, interest income, income tax benefit, and depreciation and amortization expense. Adjusted EBITDA reflects adjustments to EBITDA to identify items that, in management's judgment, significantly affect the assessment of earnings results between periods. This information is provided in order to allow investors to make meaningful comparisons of the Company's earnings performance between periods and to view the Company's business from the same perspective as Company management. As the Company cannot predict the timing and amount of charges that include, but are not limited to, items such as product recalls and related costs, restructuring programs, acquisition, integration, divestiture, and related costs, loss on extinguishment of debt, foreign currency exchange impact on the re-measurement of intercompany notes, mark-to-market adjustments on derivative contracts, and other items that may arise from time to time that would impact comparability, management does not consider these costs when evaluating the Company's performance, when making decisions regarding the allocation of resources, in determining incentive compensation, or in determining earnings estimates. EBITDA and adjusted EBITDA are performance measures commonly used by management to assess operating performance and incentive compensation, and the Company believes they are commonly reported and widely used by investors and other interested parties as a measure of a company's operating performance between periods and as a component of our debt covenant calculations.
Adjusted Net Sales, Adjusted Cost of Sales, Adjusted Gross Profit, Adjusted Total Operating Expenses, Adjusted Operating Income, Adjusted Total Other Expense, Adjusted Income Tax Expense (Benefit), Adjusted Net Income (Loss), and Adjusted Diluted Earnings (Loss) Per Share, Adjusting for Certain Items Affecting Comparability
Adjusted net sales, adjusted cost of sales, adjusted gross profit, adjusted total operating expenses, adjusted operating income, adjusted total other expense, adjusted income tax expense (benefit), and adjusted net income (loss) represent their respective GAAP presentation line item adjusted for items such as product recalls and related costs, restructuring programs, acquisition, integration, divestiture, and related costs, loss on extinguishment of debt, foreign currency exchange impact on the re-measurement of intercompany notes, mark-to-market adjustments on derivative contracts, and other items that may arise from time to time that would impact comparability. Management does not consider these costs when evaluating the Company's performance, when making decisions regarding the allocation of resources, in determining incentive compensation, or in determining earnings estimates. This information is provided in order to allow investors to make meaningful comparisons of the Company's earnings performance between periods and to view the Company's business from the same perspective as Company management. The Company has presented each of these adjusted Non-GAAP measures as a percentage of adjusted net sales compared to its respective reported GAAP presentation line item as a percentage of net sales. Adjusted diluted earnings (loss) per share ("Adjusted diluted EPS") is determined by dividing adjusted net income (loss) by the weighted average diluted common shares outstanding. Adjusted diluted EPS reflects adjustments to GAAP earnings (loss) per diluted share to identify items that, in management's judgment, significantly affect the assessment of earnings results between periods.
Given the inherent uncertainty regarding adjusted items in any future period, a reconciliation of forward-looking financial measures to the most directly comparable GAAP measure is not feasible.
Free Cash Flow
In addition to measuring our cash flow generation and usage based upon the operating, investing, and financing classifications included in the Condensed Consolidated Statements of Cash Flows, we also measure free cash flow (a Non-GAAP measure) which represents net cash used in operating activities, less capital expenditures and proceeds from sales of fixed assets. We believes free cash flow is an important measure of liquidity because it provides management and investors a measure of cash generated from operations that is available for mandatory payment obligations and investment opportunities such as funding acquisitions, repaying debt, repurchasing public debt, and repurchasing common stock. A reconciliation between the relevant GAAP measure of cash used in operating activities for the three months ended March 31, 2025 and 2024 calculated according to GAAP and free cash flow is presented in the attached tables.
ABOUT TREEHOUSE FOODS
TreeHouse Foods, Inc. is a leading private brands snacking and beverage manufacturer in North America. Our purpose is to engage and delight - one customer at a time. Through our customer focus and category experience, we strive to deliver excellent service and build capabilities and insights to drive mutually profitable growth for TreeHouse and for our customers. Our purpose is supported by investment in depth, capabilities and operational efficiencies which are aimed to capitalize on the long-term growth prospects in the categories in which we operate.
Additional information, including TreeHouse's most recent statements on Forms 10-Q and 10-K, may be found at TreeHouse's website, http://www.treehousefoods.com .
FORWARD-LOOKING STATEMENTS
This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements and other information are based on our beliefs, as well as assumptions made by us, using information currently available. The words "believe," "estimate," "project," "expect," "anticipate," "plan," "intend," "foresee," "should," "would," "could," and similar expressions, as they relate to us, are intended to identify forward-looking statements. Such statements reflect our current views with respect to future events and are subject to certain risks, uncertainties, and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, or intended. We do not intend to update these forward-looking statements following the date of this press release. Such forward-looking statements, because they relate to future events, are by their very nature subject to many important factors that could cause actual results to differ materially from those contemplated by the forward-looking statements contained in this press release and other public statements we make. Such factors include, but are not limited to: risks related to quality issues, disruptions, or inefficiencies in our supply chain and/or operations; product recalls; loss or consolidation of key suppliers; raw material and commodity costs due to inflation; labor strikes or work stoppages; multiemployer pension plans; labor shortages and increased competition for labor; success of our restructuring programs; our level of indebtedness and related obligations; disruptions in the financial markets; uncertain effects, both direct and indirect, of changes and volatility in tariffs and trade policies; interest rates; changes in foreign currency exchange rates; customer concentration and consolidation; competition; our ability to execute on our business strategy; our ability to continue to make acquisitions and execute on divestitures or effectively manage the growth from acquisitions; impairment of goodwill or long lived assets; changes and developments affecting our industry, including customer preferences and the prevalence of weight loss drugs; the outcome of litigation and regulatory proceedings to which we and/or our customers may be a party; changes in laws and regulations applicable to us; shareholder activism; disruptions in or failures of our information technology systems; geopolitical events; changes in weather conditions, climate changes, and natural disasters; and other risks that are set forth in the Risk Factors section, the Legal Proceedings section, the Management's Discussion and Analysis of Financial Condition and Results of Operations section, and other sections of our Annual Report on Form 10-K for the year ended December 31, 2024, and from time to time in our filings with the Securities and Exchange Commission ("SEC"). You are cautioned not to unduly rely on such forward-looking statements, which speak only as of the date made when evaluating the information presented in this press release. TreeHouse expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statement contained herein, to reflect any change in its expectations with regard thereto, or any other change in events, conditions or circumstances on which any statement is based.
FINANCIAL INFORMATION
TREEHOUSE FOODS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited, in millions, except per share data)
March 31, 2025
December 31, 2024
Assets
Current assets:
Cash and cash equivalents
$ 16.4
$ 289.6
Receivables, net
132.7
146.8
Inventories
589.2
539.3
Prepaid expenses and other current assets
37.2
34.0
Total current assets
775.5
1,009.7
Property, plant, and equipment, net
757.5
748.6
Operating lease right-of-use assets
190.9
154.4
Goodwill
1,889.1
1,819.3
Intangible assets, net
278.7
212.9
Other assets, net
35.6
35.1
Total assets
$ 3,927.3
$ 3,980.0
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable
$ 509.4
$ 602.5
Accrued expenses
165.9
141.3
Current portion of long-term debt
5.4
1.1
Total current liabilities
680.7
744.9
Long-term debt
1,417.4
1,401.3
Operating lease liabilities
153.8
125.4
Deferred income taxes
104.6
105.8
Other long-term liabilities
51.9
53.7
Total liabilities
2,408.4
2,431.1
Commitments and contingencies
Stockholders' equity:
Preferred stock, par value $0.01 per share, 10.0 shares authorized, none issued


Common stock, par value $0.01 per share, 90.0 shares authorized, 50.4 and 50.2
shares outstanding as of March 31, 2025 and December 31, 2024, respectively
0.6
0.6
Treasury stock
(385.4)
(385.4)
Additional paid-in capital
2,240.0
2,238.4
Accumulated deficit
(253.8)
(222.0)
Accumulated other comprehensive loss
(82.5)
(82.7)
Total stockholders' equity
1,518.9
1,548.9
Total liabilities and stockholders' equity
$ 3,927.3
$ 3,980.0
TREEHOUSE FOODS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, in millions, except per share data)
Three Months Ended
March 31,
2025
2024
Net sales
$ 792.0
$ 820.7
Cost of sales
676.8
708.7
Gross profit
115.2
112.0
Operating expenses:
Selling and distribution
36.4
42.9
General and administrative
55.7
55.8
Amortization expense
13.1
12.1
Other operating expense, net
15.5
6.4
Total operating expenses
120.7
117.2
Operating loss
(5.5)
(5.2)
Other expense:
Interest expense
19.3
15.6
Interest income
(2.8)
(4.0)
Loss on extinguishment of debt
2.6

(Gain) loss on foreign currency exchange
(0.3)
3.4
Other expense (income), net
19.3
(4.9)
Total other expense
38.1
10.1
Loss before income taxes
(43.6)
(15.3)
Income tax benefit
(11.8)
(3.6)
Net loss
$ (31.8)
$ (11.7)
Earnings (loss) per common share:
Basic
$ (0.63)
$ (0.22)
Diluted
(0.63)
(0.22)
Weighted average common shares:
Basic
50.3
53.8
Diluted
50.3
53.8
TREEHOUSE FOODS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, in millions)
Three Months Ended
March 31,
2025
2024
Cash flows from operating activities:
Net loss
$ (31.8)
$ (11.7)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
41.4
36.6
Stock-based compensation
5.6
5.7
Loss on extinguishment of debt
2.6

Unrealized loss (gain) on derivative contracts
17.0
(7.0)
Other, net
(0.9)
5.0
Changes in operating assets and liabilities, net of acquisitions:
Receivables
27.5
2.9
Inventories
(8.0)
(9.6)
Prepaid expenses and other assets
(14.4)
(8.4)
Accounts payable
(103.2)
(48.2)
Accrued expenses and other liabilities
10.7
(17.7)
Net cash used in operating activities
(53.5)
(52.4)
Cash flows from investing activities:
Capital expenditures
(25.9)
(28.3)
Proceeds from sales of fixed assets
4.1
0.2
Acquisition, net of cash acquired
(209.3)

Net cash used in investing activities
(231.1)
(28.1)
Cash flows from financing activities:
Borrowings under Revolving Credit Facility
697.3

Payments under Revolving Credit Facility
(672.3)

Payments on financing lease obligations
(0.3)
(0.1)
Payment of deferred financing costs
(3.7)

Payments on Term Loans
(905.0)

Proceeds from refinanced Term Loans
899.2

Repurchases of common stock

(43.9)
Payments related to stock-based award activities
(4.0)
(3.8)
Net cash provided by (used in) financing activities
11.2
(47.8)
Effect of exchange rate changes on cash and cash equivalents
0.2
(0.2)
Net decrease in cash and cash equivalents
(273.2)
(128.5)
Cash and cash equivalents, beginning of period
289.6
320.3
Cash and cash equivalents, end of period
$ 16.4
$ 191.8
Three Months Ended
March 31,
2025
2024
Supplemental cash flow disclosures:
Interest paid
$ 27.2
$ 26.3
Net income taxes paid
0.9
0.6
Non-cash investing and financing activities:
Capital expenditures incurred but not yet paid
15.9
11.7
Right-of-use assets obtained in exchange for lease obligations
40.9
(1.7)
Preliminary purchase price adjustment for private brand tea business acquisition
2.0

Accrued deferred financing costs
0.2

The following table reconciles the Company's net loss to EBITDA and adjusted EBITDA, for the three months ended March 31, 2025 and 2024:
TREEHOUSE FOODS, INC.
RECONCILIATION OF NET LOSS TO EBITDA AND ADJUSTED EBITDA
(Unaudited, in millions)
Three Months Ended March 31,
2025
2024
Net loss (GAAP)
$ (31.8)
$ (11.7)
Interest expense
19.3
15.6
Interest income
(2.8)
(4.0)
Income tax benefit
(11.8)
(3.6)
Depreciation and amortization
41.4
36.6
EBITDA (Non-GAAP)
14.3
32.9
Mark-to-market adjustments(1)
17.0
(7.0)
Restructuring programs & other, excluding accelerated depreciation(2)
15.4
6.7
Product recalls and related costs(3)
5.9
6.9
Loss on extinguishment of debt(4)
2.6

Acquisition, integration, divestiture, and related costs(5)
2.5
4.1
Foreign currency (gain) loss on re-measurement of intercompany notes(6)
(0.2)
2.4
Adjusted EBITDA (Non-GAAP)
$ 57.5
$ 46.0
% of net sales
Net loss margin
(4.0) %
(1.4) %
EBITDA margin
1.8 %
4.0 %
% of adjusted net sales
Adjusted EBITDA margin
7.2 %
5.6 %
During the three months ended March 31, 2025 and 2024, the Company entered into transactions that affected the year-over-year comparison of its financial results as follows:
(1)
The Company's derivative contracts are marked-to-market each period. The non-cash unrealized changes in fair value recognized in Other expense (income), net within the Condensed Consolidated Statements of Operations are treated as Non-GAAP adjustments. As the contracts are settled, realized gains and losses are recognized, and only the mark-to-market impacts are treated as Non-GAAP adjustments.
(2)
The Company's restructuring and margin improvement activities are part of an enterprise-wide transformation to improve the long-term profitability of the Company. During the first quarter of 2025, the Company recognized $2.9 million of accelerated depreciation within the Company's restructuring activities as depreciation expense.
(3)
Griddle Recall and Related Costs
On October 18, 2024, the Company initiated a voluntary recall of certain frozen waffle products produced at its Brantford, Ontario, Canada facility, and on October 22, 2024, the Company expanded its voluntary recall to include all products manufactured at the Brantford facility that are still within their shelf-life. For the three months ended March 31, 2025, the Company recognized incremental charges of $5.8 million, which includes $5.5 million for estimated product returns and claims and non-cash inventory write-offs of $0.3 million.
Broth Recall and Related Costs
On September 22, 2023, the Company initiated a voluntary recall of certain broth products produced at its Cambridge, Maryland facility and has since been executing a turnaround plan to restore the facility operations. As a result of these restoration activities, during the three months ended March 31, 2025, the Company incurred $0.1 million of costs. During the three months ended March 31, 2024, the Company incurred incremental costs related to the product recall of $6.9 million, which include non-cash plant shutdown charges of $4.4 million, non-cash inventory write-offs of $2.3 million, and other costs, including product returns and logistics, of $0.2 million.
(4)
During the three months ended March 31, 2025, the Company incurred a loss on extinguishment of debt, which included a write off of deferred financing costs of $2.6 million in connection with the Credit Agreement refinancing.
(5)
Acquisition, integration, divestiture, and related costs represents costs associated with completed and potential acquisitions, the related integration of the acquisitions, completed and potential divestitures, and gains or losses on the divestiture of a business. During the three months ended March 31, 2025, $1.9 million was classified in Cost of sales, $0.3 million was classified in General and administrative, and $0.3 million was classified in Net sales. During the three months ended March 31, 2024, $2.0 million was classified in General and administrative, $1.9 million was classified in Cost of sales, and $0.2 million was classified in Other operating expense, net.
(6)
The Company has foreign currency denominated intercompany loans and incurred foreign currency gains/losses to re-measure the loans at quarter end. These amounts are non-cash and the loans are eliminated in consolidation.
The following tables reconcile the Company's Adjusted net sales, Adjusted cost of sales, Adjusted gross profit, Adjusted total operating expenses, Adjusted operating income, Adjusted total other expense, Adjusted income tax expense (benefit), and Adjusted net income (loss) to their most directly comparable GAAP measure, for three months ended March 31, 2025 and 2024:
TREEHOUSE FOODS, INC.
RECONCILIATION OF NON-GAAP MEASURES
(Unaudited, in millions, except per share amounts)
Three Months Ended March 31, 2025
Net sales
Cost of
sales
Gross
profit
Total
operating
expenses
Operating
(loss)
income
Total
other
expense
Income
tax
(benefit)
expense
Net (loss)
income
As reported (GAAP)
$ 792.0
$ 676.8
$ 115.2
$ 120.7
$ (5.5)
$ 38.1
$ (11.8)
$ (31.8)
Adjustments:
Mark-to-market adjustments(1)





(17.0)

17.0
Restructuring programs & other, including accelerated
depreciation(2)

(2.8)
2.8
(15.5)
18.3


18.3
Product recalls and related costs(3)
3.7
0.1
3.6
(2.3)
5.9


5.9
Loss on extinguishment of debt(4)





(2.6)

2.6
Acquisition, integration, divestiture, and related costs(5)
0.3
(1.9)
2.2
(0.3)
2.5


2.5
Foreign currency gain on re-measurement of intercompany notes(6)





0.2

(0.2)
Taxes on adjusting items






12.8
(12.8)
As adjusted (Non-GAAP)
$ 796.0
$ 672.2
$ 123.8
$ 102.6
$ 21.2
$ 18.7
$ 1.0
$ 1.5
As reported (% of net sales)
14.5 %
15.2 %
(0.7) %
4.8 %
(1.5) %
(4.0) %
As adjusted (% of adjusted net sales)
15.6 %
12.9 %
2.7 %
2.3 %
0.1 %
0.2 %
Earnings (loss) per share:
Diluted
$ (0.63)
Adjusted diluted
$ 0.03
Weighted average common shares:
Diluted for net loss
50.3
Diluted for adjusted net income
50.4
Three Months Ended March 31, 2024
Net sales
Cost of
sales
Gross
profit
Total
operating
expenses
Operating
(loss)
income
Total
other
expense
Income
tax benefit
Net loss
As reported (GAAP)
$ 820.7
$ 708.7
$ 112.0
$ 117.2
$ (5.2)
$ 10.1
$ (3.6)
$ (11.7)
Adjustments:
Mark-to-market adjustments(1)





7.0

(7.0)
Restructuring programs & other(2)



(6.7)
6.7


6.7
Product recalls and related costs(3)
0.9
(6.0)
6.9

6.9


6.9
Acquisition, integration, divestiture, and related costs(5)

(1.9)
1.9
(2.2)
4.1


4.1
Foreign currency loss on re-measurement of intercompany notes(6)





(2.4)

2.4
Taxes on adjusting items






3.2
(3.2)
As adjusted (Non-GAAP)
$ 821.6
$ 700.8
$ 120.8
$ 108.3
$ 12.5
$ 14.7
$ (0.4)
$ (1.8)
As reported (% of net sales)
13.6 %
14.3 %
(0.6) %
1.2 %
(0.4) %
(1.4) %
As adjusted (% of adjusted net sales)
14.7 %
13.2 %
1.5 %
1.8 %
— %
(0.2) %
Earnings (loss) per share
Diluted
$ (0.22)
Adjusted diluted
$ (0.03)
Weighted average common shares:
Diluted for net loss
53.8
Diluted for adjusted net loss
53.8
TREEHOUSE FOODS, INC.
RECONCILIATION OF NET CASH USED IN OPERATING ACTIVITIES TO FREE CASH FLOW
(Unaudited, in millions)
Three Months Ended
March 31,
2025
2024
Cash flow used in operating activities (GAAP)
$ (53.5)
$ (52.4)
Capital expenditures
(25.9)
(28.3)
Proceeds from sales of fixed assets
4.1
0.2
Free cash flow (Non-GAAP)
$ (75.3)
$ (80.5)
Cision
View original content:https://www.prnewswire.com/news-releases/treehouse-foods-inc-reports-first-quarter-2025-results-302446453.html
SOURCE TreeHouse Foods, Inc.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC
The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC

Yahoo

timean hour ago

  • Yahoo

The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC

CHENGDU, China, June 6, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", today announced that results from its registrational study (OptiTROP-Lung03) evaluating sacituzumab tirumotecan (sac-TMT) versus docetaxel in patients with previously treated advanced EGFR-mutant non-small cell lung cancer (NSCLC) have been published in The British Medical Journal (impact factor: 93.6). These data were also presented as an oral presentation in the Lung Cancer—Non–Small Cell Metastatic session (Abstract #8507) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Based on the encouraging data from this study, sac-TMT was approved for marketing by the National Medical Products Administration (NMPA) for the treatment of adult patients with epidermal growth factor receptor (EGFR) mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy in March 2025. This marks the first global approval of a TROP2 ADC for a lung cancer indication. The published results are based on OptiTROP-Lung03, an open-label, randomized, multicenter registrational study evaluating the efficacy and safety profile of sac-TMT monotherapy versus docetaxel for the treatment of patients with locally advanced or metastatic EGFR-mutant NSCLC who have failed after treatment with an EGFR-TKI and platinum-based chemotherapy. A total of 137 patients with advanced EGFR-mutant NSCLC who had progressed after EGFR-TKI and platinum-based chemotherapy were randomized (2:1) to receive sac-TMT (5 mg/kg once every 2 weeks) or docetaxel (75 mg/m2 once every 3 weeks) until disease progression, intolerable toxicity or other reason for discontinuation, with a median follow-up time of 12.2 months (Data cutoff date: December 31, 2024). Sac-TMT achieved statistically significant and clinically meaningful outcomes compared to docetaxel: Confirmed objective response rate (ORR) (As assessed by blinded independent review committee (BIRC): 45% (95% CI, 35-56) vs 16% (95% CI, 7-30). Median progression-free survival (PFS) (As assessed by BIRC: 6.9 months [sac-TMT; 95% CI, 5.4-8.2] vs 2.8 months [docetaxel; 95% CI, 1.6-4.1], hazard ratio (HR)= 0.30 [range, 0.20 -0.46], one-sided p<0.0001; as assessed by investigator (INV): 7.9 months [sac-TMT; 95% CI, 6.2-9.5] vs 2.8 months [docetaxel; 95% CI, 1.5-3.8], HR=0.23 [95% CI, 0.15-0.36], one-sided p<0.0001). With 36.4% of patients in docetaxel group crossing over to receive sac-TMT, median overall survival (OS) was not reached (NR) for both groups (HR=0.49; 95% CI, 0.27-0.88; one-sided p=0.007). The median OS analysed by pre-specified rank-preserving structural failure time (RPSFT) model adjusted for crossover was 9.3 months for docetaxel and NR for sac-TMT (HR=0.36; 95% CI, 0.20-0.66). Efficacy benefit favored patients with sac-TMT over docetaxel across all pre-specified subgroups, including prior EGFR-TKI therapy, brain metastases, EGFR mutation type, etc. Grade ≥ 3 treatment-related adverse events (TRAEs) occurred in 56.0% of patients in sac-TMT group vs 71.7% in docetaxel group. The results demonstrated that sac-TMT monotherapy achieved statistically significant and clinically meaningful improvements in objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) compared to docetaxel, with a manageable safety profile. Sac-TMT is being extensively studied in the NSCLC field. Covering treatment settings from later-line therapy to early-stage postoperative adjuvant therapy, including both monotherapy and combination regimens. Currently, five company-led registrational clinical studies for sac-TMT in NSCLC are underway in China. Meanwhile, Merck Sharp & Dohme(the tradename of Merck & Co., Inc., Rahway, NJ, USA)is also conducting five global Phase III clinical trials of sac-TMT for NSCLC in regions where it has exclusive rights. Professor Li Zhang, National Lead Principal Investigator, Medical Oncologist and Deputy Director of the Lung Cancer Research Centre at Sun Yat-Sen University, stated: "EGFR mutation is the most common driver alteration in NSCLC. The prevalence of EGFR mutations reaches 28.2% among NSCLC patients in China. Although third-generation EGFR-TKIs have become the standard of care for advanced EGFR-mutant NSCLC and may significantly improve PFS, acquired resistance remains inevitable. Combining EGFR-TKIs with chemotherapy can offer additional survival benefits to some patients, but this approach is limited by safety concerns and may compromise future treatment options, posing significant clinical challenges. The publication of the OptiTROP-Lung03 study in the British Medical Journal marks a major milestone—not only highlighting international recognition of this study outcomes in lung cancer, but also demonstrating the global competitiveness of sac-TMT as a novel TROP2 ADC." Dr. Michael Ge, CEO of Kelun-Biotech, commented: "We are thrilled to see the OptiTROP-Lung03 study published in a top-tier journal. Currently, EGFR-TKIs and chemotherapy remain the standard of care for patients with EGFR-mutant advanced NSCLC, but the challenge of increasing efficacy with manageable tolerability. The results from OptiTROP-Lung03 highlight significant survival benefits with manageable safety profile and suggest that sac-TMT could emerge as a new standard of care for this population. We remain committed to working with our partners to establish sac-TMT as a new standard of care for this patient population and improve outcomes for lung cancer patients worldwide." Registrational Study Led by Kelun-Biotech OptiTROP-Lung03: Sac-TMT monotherapy versus docetaxel for locally advanced or metastatic EGFR-mutant NSCLC after treatment failure with EGFR-TKI and platinum-containing chemotherapy; OptiTROP-Lung04: Sac-TMT monotherapy versus pemetrexed in combination with platinum for locally advanced or metastatic non-squamous NSCLC with EGFR mutations that have failed EGFR-TKI therapy; OptiTROP-Lung05: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for first-line treatment of PD-L1-positive locally advanced or metastatic NSCLC; OptiTROP-Lung06: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for the first-line treatment of PD-L1-negative locally advanced or metastatic non-squamous NSCLC; OptiTROP-Lung07: First-line treatment of locally advanced or metastatic NSCLC with EGFR mutations by sac-TMT in combination with ositinib. Registrational Study Led by MSD NSCLC not achieving a pCR after neoadjuvant therapy followed by surgery. NSCLC expressing PD-L1 >50% pre-treated NSCLC with EGFR mutations or other genomic alterations EGFR-mutated, advanced non-squ NSCLC progressed on prior EGFR-TK metastatic sg NSCLC About sac-TMT Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, BC, gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macao, and Taiwan). To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) based on the OptiTROP-Breast01 study and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy based on the OptiTROP-Lung03 study. Sac-TMT became the first domestic ADC with global intellectual property rights to be fully approved for marketing. It is also the world's first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the National Medical Products Administration (NMPA), and were reviewed via the priority review and approval process. As of today, the Company has initiated 8 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other agents for several types of cancer. These studies are sponsored and led by MSD. About Kelun-Biotech Kelun-Biotech( a holding subsidiary of Kelun Pharmaceutical ( which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel coupled drug products in clinical or preclinical research stage. For more information, please visit Media: klbio_pr@ View original content to download multimedia: SOURCE Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Here's How You Can Earn $100 In Passive Income By Investing In Air Products And Chemicals Stock
Here's How You Can Earn $100 In Passive Income By Investing In Air Products And Chemicals Stock

Yahoo

timean hour ago

  • Yahoo

Here's How You Can Earn $100 In Passive Income By Investing In Air Products And Chemicals Stock

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Air Products and Chemicals Inc. (NYSE:APD) provides atmospheric gases, process and specialty gases, equipment, and related services globally. The 52-week range of Air Products and Chemicals stock price was $243.69 to $341.14. Air Products and Chemicals' dividend yield is 2.57%. It paid $7.16 per share in dividends during the last 12 months. Don't Miss: Invest Where It Hurts — And Help Millions Heal: Maximize saving for your retirement and cut down on taxes: . On May 1, the company announced its Q2 2025 earnings, posting revenues of $2.92 billion, missing the consensus estimate of $2.93 billion, as reported by Benzinga. Adjusted EPS fell 6% year-over-year to $2.69, missing the $2.83 consensus, as lower volumes and higher costs were partly offset by strong pricing. The company expects Q3 adjusted EPS of $2.90 to $3, compared to the consensus of $3.28. For full-year 2025, the adjusted EPS is expected to be between $11.85 and $12.15, lowered from the prior range of $12.70 to $13, and missing the consensus of $12.55. Check out this article by Benzinga for nine analysts' insights on Air Products and Chemicals. Trending: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." If you want to make $100 per month — $1,200 annually — from Air Products dividends, your investment value needs to be approximately $46,693, which is around 168 shares at $278.70 each. Understanding the dividend yield calculations: When making an estimate, you need two key variables — the desired annual income ($1,200) and the dividend yield (2.57% in this case). So, $1,200 / 0.0257 = $46,693 to generate an income of $100 per month. You can calculate the dividend yield by dividing the annual dividend payments by the current price of the stock. The dividend yield can change over time. This is the outcome of fluctuating stock prices and dividend payments on a rolling instance, assume a stock that pays $2 as an annual dividend is priced at $50. Its dividend yield would be $2/$50 = 4%. If the stock price rises to $60, the dividend yield drops to 3.33% ($2/$60). A drop in stock price to $40 will have an inverse effect and increase the dividend yield to 5% ($2/$40). In summary, income-focused investors may find Air Products stock an attractive option for making a steady income of $100 per month by owning 168 shares of stock. There may be more upside to come as investors benefit from the company's consistent dividend hikes. Air Products and Chemicals has raised its dividend consecutively for the last 43 years. Lower interest rates mean some investments won't yield what they did in months past, but you don't have to lose those gains. Certain private market real estate investments are giving retail investors the opportunity to capitalize on these high-yield opportunities. , which provides access to a pool of short-term loans backed by residential real estate. The best part? Unlike other private credit funds, Looking for fractional real estate investment opportunities? The features the latest offerings. Image: Shutterstock This article Here's How You Can Earn $100 In Passive Income By Investing In Air Products And Chemicals Stock originally appeared on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Bernstein Sticks to Its Buy Rating for Centene (CNC)
Bernstein Sticks to Its Buy Rating for Centene (CNC)

Business Insider

timean hour ago

  • Business Insider

Bernstein Sticks to Its Buy Rating for Centene (CNC)

Bernstein analyst Lance Wilkes maintained a Buy rating on Centene (CNC – Research Report) today and set a price target of $86.00. The company's shares closed today at $55.16. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Wilkes covers the Healthcare sector, focusing on stocks such as UnitedHealth, Humana, and Elevance Health. According to TipRanks, Wilkes has an average return of -0.3% and a 42.86% success rate on recommended stocks. In addition to Bernstein, Centene also received a Buy from Wells Fargo's Stephen Baxter in a report issued yesterday. However, on June 2, Barclays downgraded Centene (NYSE: CNC) to a Hold.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store